CRDL Stock Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.44 |
| 52 Week High | CA$2.94 |
| 52 Week Low | CA$0.74 |
| Beta | 0.71 |
| 1 Month Change | 20.79% |
| 3 Month Change | 69.44% |
| 1 Year Change | 208.86% |
| 3 Year Change | -34.93% |
| 5 Year Change | -56.35% |
| Change since IPO | -41.20% |
Recent News & Updates
Recent updates
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
Jan 06
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
Sep 13We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
May 24We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Jan 20We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Aug 10We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
Apr 17Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Dec 09We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
Aug 19Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Apr 18Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth
Jan 03Shareholder Returns
| CRDL | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 1.2% | -1.8% | -0.6% |
| 1Y | 208.9% | 50.8% | 3.9% |
Return vs Industry: CRDL exceeded the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: CRDL exceeded the Canadian Market which returned 3.9% over the past year.
Price Volatility
| CRDL volatility | |
|---|---|
| CRDL Average Weekly Movement | 18.8% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CRDL's share price has been volatile over the past 3 months.
Volatility Over Time: CRDL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CRDL fundamental statistics | |
|---|---|
| Market cap | CA$166.61m |
| Earnings (TTM) | -CA$28.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs CRDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$28.13m |
| Earnings | -CA$28.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRDL perform over the long term?
See historical performance and comparison